Q2 2026 saw 4% comparable sales growth and a 400 bps increase in adjusted EBITA margin, driven by a US tariff refund. All segments grew, with Personal Health leading, and productivity initiatives delivered significant savings. 2026 outlook was raised for EBITA margin and free cash flow.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.